Key Highlights
• BillionToOne will occupy approximately 62,659 sq ft of laboratory and office space at 3260 Whipple Road, Union City.
• The 12-year lease includes base rent totaling approximately $46.7 million and financial support for tenant improvements.
• The new facility will increase the company’s total operational space by roughly 16% and significantly expand oncology lab capacity.
BillionToOne, Inc. (NASDAQ: BLLN) announced on June 23, 2026, that it has finalized a long-term lease for additional laboratory and office space in Northern California. The move is intended to bolster the company’s capacity for oncology testing and accommodate increasing demand for its diagnostic services in the life sciences sector.
Lease Scope
The agreement provides BillionToOne with approximately 62,659 sq ft at 3260 Whipple Road, Union City, CA 94587. The space is designed to support both administrative functions and specialized laboratory operations, with a focus on expanding the company’s oncology testing capabilities. The location is situated in a growing hub for biotechnology and medical research firms.
Financial Terms
Under the terms of the lease, the total base rent over the 12-year period is approximately $46.7 million. The landlord has agreed to an initial rent abatement period and will provide financial support for customizing the space to meet the company’s operational needs. A security deposit of $407,910 is required at the time of signing.
These terms reflect a commitment to fostering long-term growth in a competitive real estate market for life sciences facilities.
Facility Expansion
The new space will increase BillionToOne’s total facility footprint by roughly 16%, enabling the company to scale its operations. The expansion is particularly significant for oncology-related testing, where demand has been rising due to advancements in precision medicine and increased focus on early cancer detection. The additional capacity is expected to support higher test volumes and improve turnaround times for clinical partners.
Timeline and Options
The lease is scheduled to commence on or around August 1, 2027, following the completion of necessary build-out work. The agreement also includes an option to extend the lease for an additional ten years at market rates, providing flexibility for future operational planning. This long-term arrangement aligns with the company’s strategic goals in a sector where stable facility access is critical.
Regulatory Filing
The details of the lease will be included as part of BillionToOne’s Form 10-Q filing for the quarter ended June 30, 2026. The disclosure complies with the Securities Exchange Act of 1934, ensuring transparency for investors and stakeholders regarding the company’s expansion activities.
Strategic Context
The lease reflects BillionToOne’s confidence in the continued growth of its oncology testing platform. By securing dedicated laboratory space in a key biotech region, the company is positioning itself to meet rising demand while maintaining operational efficiency. The move underscores the importance of scalable infrastructure in supporting innovation and commercialization in the life sciences industry.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...